2020
DOI: 10.1016/j.jacc.2019.11.044
|View full text |Cite
|
Sign up to set email alerts
|

Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
135
0
8

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 154 publications
(144 citation statements)
references
References 181 publications
1
135
0
8
Order By: Relevance
“…A novel model of cardiometabolic-based chronic disease (CMBCD) including adiposity-based chronic disease (ABCD, defined as abnormalities in the amount, distribution, and function of adipose tissue) and dysglycemia-based chronic disease (DBCD) is now proposed ‘to provide a basis for early and sustainable, evidence-based therapeutic targeting to promote cardiometabolic health and mitigate the development and ravages of cardiovascular disease’. 48 CMBCD focuses on three primary drivers (genetics, environment, and behavior) and two metabolic drivers (adiposity and dysglycemia). Insulin resistance is at the intersection between ABCD and DBCD, and further weight gain can worsen insulin resistance and intensify inflammation, oxidative stress, and glucose intolerance.…”
Section: Discussionmentioning
confidence: 99%
“…A novel model of cardiometabolic-based chronic disease (CMBCD) including adiposity-based chronic disease (ABCD, defined as abnormalities in the amount, distribution, and function of adipose tissue) and dysglycemia-based chronic disease (DBCD) is now proposed ‘to provide a basis for early and sustainable, evidence-based therapeutic targeting to promote cardiometabolic health and mitigate the development and ravages of cardiovascular disease’. 48 CMBCD focuses on three primary drivers (genetics, environment, and behavior) and two metabolic drivers (adiposity and dysglycemia). Insulin resistance is at the intersection between ABCD and DBCD, and further weight gain can worsen insulin resistance and intensify inflammation, oxidative stress, and glucose intolerance.…”
Section: Discussionmentioning
confidence: 99%
“…For the first time, CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) showed that inhibition of the interleukin (IL)-1b pathway in patients with CAD could reduce the risk of cardiovascular events by approximately 17% [ 7 ]. Actually, insulin resistance (IR), which has a strong relationship with dyslipidemia and inflammation [ 8 ], has not received much attention. The residual risk after lipid-lowering agents could be attributed to IR to a large degree [ 9 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…Due to the limitations of BMI, which cannot distinguish fat mass and lean mass [6,9], recent evidences support that considering the presence or absence of combined metabolic abnormality in addition to obesity defined on the basis of BMI can more effectively stratify the prognostic implication of obesity as a risk factor of cardiovascular diseases (CVDs) including HF [10][11][12][13]. As a result, concepts of unique obesity sub-phenotypes, including metabolically healthy obesity (MHO) and metabolically unhealthy non-obesity (MUNO) have emerged.…”
mentioning
confidence: 99%